RNAble

Modulating RNA Epitranscriptomics

Health Tech & Life Sciences
Active
Seed Ness Ziona Founded 2021
Total raised
Last: Seed 2022-01
Stage
Seed
Founded
2021
Headcount
6
HQ
Ness Ziona
Sector
Health Tech & Life Sciences

About

RNAble is developing novel compounds that alter RNA stability through modulation of RNA epitranscriptomics for the treatment of specific cancers and rare genetic diseases with nonsense mutations.

RNA transcripts undergo modifications that are recognized by specific RNA-binding proteins dictating their stability. Professor Rotem Karni, RNAble inventor, discovered that targeting components of the RNA epitranscriptomic machinery with small molecules resulted in the stabilization of several RNAs, including unstable nonsense mutated transcripts which are degraded by the nonsense-mediated decay machinery.

This discovery opens the possibility of restoring the expression of mutated genes essential to rare diseases and suppressing the growth of specific cancers.

Funding history · 1 round · — total

2022-01
Seed Undisclosed

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesBiotechnology
Business model
B2B

Tags

cancerrare-diseasespharmaceuticalsgenetic-disorderscancer-therapy